Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder

Urology

Volumn 67, Issue 4, 2006, Pages 756-761

  Babjuk, M ^a   Soukup, V ^a   Mares J ^a   Duskova J ^a   Pecen, L ^b   Pesl M ^a   Pavlik I ^a   DvorRcek J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF COMPUTER SCIENCE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR PAX5;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTOSCOPY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATHOLOGY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINE CYTOLOGY; UROGENITAL TRACT TUMOR;

ADULT; AGED; AGED, 80 AND OVER; B-CELL-SPECIFIC ACTIVATOR PROTEIN; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RNA, MESSENGER; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33646472153     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.10.053     Document Type: Article

References (15)

1. Lamm D.L. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19 (1992) 573-580
2. Heney N.M., Ahmed S., Flanaghan M.J., et al. Superficial bladder cancer. progression and recurrence. J Urol 130 (1983) 1083-1086
3. Urbänek P., Wang Z.-Q., Fetka I., Wagner E.F., et al. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 79 (1994) 901-912
4. Nutt S.L., Thevenin C., and Busslinger M. Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiology 198 (1997) 227-235
5. Stuart E.T., Kioussi C., Aguzzi A., et al. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1 (1995) 207-214
6. Kozmik Z., Sure U., Rüedi D., et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci U S A 92 (1995) 5709-5713
7. Tiacci E., Pileri S., Orleth A., et al. PAX5 expression in acute leukemias. higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res 64 (2004) 7399-7404
8. Baumann Kubetzko F.B., Di Paolo C., Maag C., et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 25 (2004) 1839-1846
9. Adshead J.M., Ogden C.W., Penny M.A., et al. The expression of PAX5 in human transitional cell carcinoma of the bladder. relationship with de-differentiation. BJU Int 83 (1999) 1039-1044
10. Sobin L.H., and Wittekind C. UICC TNM Classification of Malignant Tumours. 5th ed (1997), Wiley Liss, New York pp 187-190
11. Oosterlinck W., Lobel B., Jakse G., et al. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
12. Maulbecker C.C., and Gruss P. The oncogenic potential of Pax genes. EMBO J 12 (1993) 2361-2397
13. Schäfer B.W. Emerging roles for PAX transcription factors in cancer biology. Gen Physiol Biophys 17 (1998) 211-224
14. Muratovska A., Zhou C., He S., et al. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22 (2003) 7989-7997
15. Orlow I., Lianes P., Lacombe L., et al. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res 54 (1994) 2848-2851